The history of the erectile dysfunction drug presents a complex picture for investors. While the initial introduction generated massive returns, the lapse of its intellectual property protection opened the avenue to off-brand alternatives, dramatically diminishing revenue. This presents a particular risk for pharmaceutical companies depending on si

The history of Viagra, and its parent company copyright, presents a intriguing case study for investors. At first a blockbuster drug, yielding billions in income, its exclusivity period created a wave of generic competition , significantly diminishing its dominance. While some firms may try to capitalize on male sexual dysfunction, the existing lan